Gynecological cytodiagnosis and HPV
The most common cause of cervical cancer is chronic infection with high-risk types of the human papilloma virus (HPV). Over 99 % of all cases of cervical cancer are associated with this infection.
Medical screenings allow cancer precursors to be detected and dealt with early. As a result, the frequency of cervical cancer and the mortality rate can be reduced drastically.
In addition to gynecological cytodiagnostics (Pap smear), Viollier offers high-risk HPV screening (types 16, 18, and other high-risk types globally without genotyping) as well as complete HPV genotyping.
Cervical smears are assessed using the Hologic ThinPrep® Pap TestTM, which tests samples using the thin smear method. It is the most popular thin smear method in Europe and the USA (FDA approval).
Sample preparation is fully automated using a tried and tested filtration method (removes mucus and blood) and standardized coloring for significantly greater ease of analysis.
The analysis is then performed by qualified cytotechnicians and cytopathologists with the aid of a computer.
Improved early detection of cervical carcinoma
- With a detection rate of 59.7 %, significantly more effective at detecting high-grade lesions in comparison to conventional smear tests (FDA).
- Improved safety thanks to standardized quality at the same price
Improved molecular biological diagnostics using an optimal preservation medium to detect other sexually transmitted diseases: HPV, chlamydia trachomatis, neisseria gonorrhoeae, Herpes simplex
Human papillomaviruses (HPV)
In addition to gynecological cytodiagnostics, the same sample material (ThinPrep® Pap TestTM) can be used directly for screening the patient for high-risk HPV (types 16, 18, and other high-risk types globally without genotyping) as well as complete HPV genotyping without additional smears.
Cumulative depiction of pap and HPV findings, with 6 Pap and 6 HPV findings being displayed on one line.
The clear separation of the Bethesda and Munich II classifications means that you can work with your preferred classification.
Each month, senders receive a list of patients with conspicuous preliminary findings for which no follow-up to the Pap smear has yet been carried out.